HilleVax reports Q3 EPS (52c), consensus (42c)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Should l Buy ?
- Company Financials: As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities totaling $189.3 million.
- Previous Financials: On December 31, 2023, these financial assets were significantly higher at $303.5 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
